Edwards: CMS finally opens the asymptomatic TAVR market — but the stock already priced it in

On September 10, the Centers for Medicare and Medicaid Services finalized a new coverage decision for transcatheter aortic valve replacement (TAVR), the minimally invasive heart valve that is Edwards Lifesciences' core product. The headline change is big: Medicare will now cover TAVR for patients with asymptomatic severe aortic stenosis — the large pool of people whose valve disease has not yet caused symptoms. For a company that built its franchise treating the sickest patients, coverage of this earlier, healthier population is the next layer of demand.

The final decision does two things at once. It extends coverage to asymptomatic patients, but only under "coverage with evidence development" (CED) — Medicare pays only when the procedure is done inside a CMS-approved clinical trial. And it drops the evidence-development requirement for symptomatic patients, moving today's biggest procedure volume to standard coverage subject to the decision's coverage criteria. Ongoing registry-based studies are folded into the standard investigational-device pathway.

That second piece is worth pausing on. For years, Edwards' dominant TAVR volumes were tied to a coverage-with-evidence framework — hospitals treating symptomatic patients were effectively enrolled in a national registry, with all the paperwork and surveillance that implies. CMS ending that condition is the quieter, more immediate win: it removes overhead from the procedures Edwards already sells by the hundreds of thousands, and signals the agency now trusts the evidence enough to treat TAVR as settled medicine.

The asymptomatic piece is newer and larger in ambition but slower in practice. It is real demand — the final decision explicitly extends coverage to this population under CED — yet the "coverage with evidence development" qualifier means volume can only build as fast as approved studies enroll patients and return data. This is a measured ramp, not a switch flipped to full open access.

Why Edwards, specifically

Edwards is the natural beneficiary because it is the company that pushed for this. It formally asked CMS to reconsider TAVR coverage in December 2025, after its Sapien 3 valve family — the Sapien 3, Sapien 3 Ultra, and Sapien 3 Ultra Resilia — won FDA approval in May 2025 for asymptomatic severe aortic stenosis, the first TAVR platform cleared for that indication. That clearance rested on the EARLY TAVR trial, which found early TAVR beat clinical surveillance at reducing death, stroke, or unplanned heart-related hospitalization. In other words, Edwards did not just win a favorable ruling; it supplied the evidence the ruling depends on, and it holds the only FDA-approved device for the newly covered patients.

The commercial record supports the leadership claim. In the second quarter, total sales rose 13.6% to $1.74 billion and TAVR sales grew 11.3% to $1.26 billion, and management raised its full-year sales and TAVR guidance. This is a growth business with a 78% gross margin and roughly a 17% free-cash-flow margin — the profile of a quality compounder, not a turnaround.

The catch is the price

Which is exactly why the reaction to today's headline is worth measuring. Edwards shares rose less than 1% on the news — a muted response to what reads as an unambiguous positive. That relative silence is itself a finding. The coverage expansion was telegraphed for nine months: the request in December, the proposed decision in June, a public-comment period that closed in mid-July, and finalization in September. The market had ample time to pay for the outcome, and it did.

The bill shows up in the multiple. Edwards trades near 50 times trailing earnings and about 36 times forward earnings, a steep premium versus roughly 22 times for Medtronic, 33 times for Abbott, and 17 times for Boston Scientific among diversified device makers. A premium that size is justified only if the asymptomatic expansion converts to procedure volume faster than the CED gating allows — and the very design of the ruling makes that gradual.

None of this makes the NCD bad news. It is genuinely good news that confirms the direction of the story: a structural tailwind, owned by the market leader, backed by its own clinical data. The question is not whether Edwards benefits, but whether it has already pocketed the benefit in the stock price. On that test, the evidence leans toward "yes": the event investors were waiting for has arrived, and the stock barely moved.

So the practical takeaway is a familiar disconnect between a good company and a good stock. The franchise quality is real — 13.6% revenue growth, dominant TAVR share, an FDA-approved platform in the newly covered population, and now CMS coverage to fund it. But at nearly 50 times trailing earnings, the easy money from this catalyst looks made. The honest stance is a wait: let the CMS-approved studies show they can enroll and convert asymptomatic patients into paid procedures at a pace the multiple implies. If they do, there may yet be upside; if enrollment is slow, a rich multiple with a gradual ramp has further to fall. The news strengthens the business and does almost nothing to change the valuation math.